tiprankstipranks
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
ARQT
Arcutis Biotherapeutics
RESEARCH TOOLSreports

Arcutis Biotherapeutics (ARQT) Stock News & Sentiment

960 Followers
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Premium
Company Announcements
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
21d ago
ARQT
Arcutis (ARQT) Earnings Call Signals Scaled Growth
Premium
Company Announcements
Arcutis (ARQT) Earnings Call Signals Scaled Growth
26d ago
ARQT
Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
Premium
Ratings
Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
1M ago
ARQT
Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
Premium
Ratings
Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
1M ago
ARQT
Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating
Premium
Ratings
Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating
1M ago
ARQT
ARQT Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ARQT Earnings this Week: How Will it Perform?
1M ago
ARQT
Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
Premium
Ratings
Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
2M ago
ARQT
More ARQT News >

ARQT News on the Web

Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis
rttnews
Bullish
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
TipRanks News
Bullish
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
TipRanks News
Bullish
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
TipRanks News
Bullish
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
TipRanks News
Bullish
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)
TipRanks News
Neutral
Arcutis Biotherapeutics (ARQT) Elevates Legal Leader to Executive Role
GuruFocus News
Neutral
Arcutis announces promotion of Matsuda to EVP, Chief Legal Officer
TipRanks News
Bullish

News Score - Last 7 Days

Positive
ARQT
Sector Average
Media Buzz
This Week2 articles
Weekly Average2.5 articles
News Sentiment
This Week100%
Sector Average66%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARQT’s Media Buzz Sentiment?
2 articles about ARQT were published this week. In an average week, 2.5 articles are published.
    What is ARQT’s weekly average amount of articles?
    In an average week, 2.5 articles about ARQT are published.
      What is ARQT’s News Sentiment?
      100% of articles about ARQT were positive this week, compared to its sector average of 66%.
        Healthcare Stocks that are Trending in the News
        DBVTDBV Technologies SA - American
        640China Resources Pharmaceutical Group Ltd.
        KODKodiak Sciences
        NKTXNkarta
        WXIBFWuxi Biologics (Cayman)
        Showing the stocks with the most bullish news sentiment over the past week